Printer Friendly

U.S. PATENT ISSUED TO IMMUNOMEDICS FOR NEW CANCER THERAPEUTICS

 U.S. PATENT ISSUED TO IMMUNOMEDICS FOR NEW CANCER THERAPEUTICS
 MORRIS PLAINS, N.J., June 9 /PRNewswire/ -- Immunomedics, Inc. (NASDAQ: IMMU) announced today that the U.S. Patent Office has issued patent 5,120,525, covering one of the company's new methods of cancer treatment.
 This method involves combining the injection of radiolabeled cancer- targeting antibodies with the administration of certain cytokines, particularly blood cell growth factors such as G-CSF and GM-CSF. Such cytokines as G-CSF, GM-CSF, IL-1, etc., are being either commercialized or tested by a large number of major pharmaceutical companies. The allowance of this patent was previously announced.
 The cytokines, covered by this patent, are hormone-like substances which stimulate white blood cell activity, potentially offsetting the adverse effects of chemotherapy or radioimmunotherapy. Immunomedics has commenced preclinical testing of this type of cancer therapeutic using cytokines in combination with one of the company's CEA (carcinoembryonic antigen)-targeting antibodies.
 "Damage to the bone marrow is one of the major limitations in achieving clinically useful response from radioimmunotherapy or chemotherapy," stated Dr. Carl Pinsky, vice president, medical affairs. "This new method of combining radioimmunotherapy with certain cytokines stimulates the bone marrow and allowed 25 percent higher doses of radioimmunotherapy to be administered in animal studies," further stated Pinsky.
 Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections or other diseases.
 -0- 6/9/92
 /CONTACT: Amy Factor of Immunomedics, 201-605-8200/
 (IMMU) CO: Immunomedics Inc. ST: New Jersey IN: MTC SU:


CK-OS -- NY021 -- 8268 06/09/92 10:01 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 9, 1992
Words:292
Previous Article:KLAUS H. RISSE TO RETIRE FROM MILES INC.
Next Article:SOUTHWESTERN BELL'S CELLULAR ONE(R) OF CHICAGO INTRODUCES FIRST CELLULAR TRAVEL INFORMATION SERVICE IN UNITED STATES
Topics:


Related Articles
IMMUNOMEDICS GRANTED U.S. PATENT FOR LABELING ANTIBODY FRAGMENTS FOR IMAGING AND THERAPY
IMMUNOMEDICS IS GRANTED TWO U.S. PATENTS
Broad Patent for Therapy and Diagnosis of Drug-Resistant Cancers and Infections Awarded to Immunomedics
Immunomedics Awarded Broad Patent Claims to Technology that Could Enhance Medicine's Ability to Detect and Treat Cancer, Infection, Clots And...
Immunomedics Awarded Two New U.S. Patents for Disease Detection and Therapy
Immunomedics Invents New Radiopharmaceutical Technologies
Immunomedics Invents New Method for Controlling Toxicities From Cancer Therapies
Immunomedics Granted Two New U.S. Patents for Improved MRI and Nuclear Imaging
Patented method could overcome drug resistance in cancer.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters